- Home
- RIGL vs TRNS Comparison
RIGL vs TRNS Comparison
Compare RIGL & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | TRNS |
|---|---|---|
| Founded | 1996 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 799.0M |
| IPO Year | 2000 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RIGL | TRNS |
|---|---|---|
| Price | $45.86 | $84.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $45.67 | ★ $116.00 |
| AVG Volume (30 Days) | ★ 206.3K | 64.9K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | 0.14 |
| Revenue | $294,282,000.00 | ★ $331,877,000.00 |
| Revenue This Year | N/A | $21.75 |
| Revenue Next Year | $12.75 | $7.55 |
| P/E Ratio | ★ $34.00 | $585.64 |
| Revenue Growth | ★ 64.15 | 19.20 |
| 52 Week Low | $24.84 | $50.23 |
| 52 Week High | $52.24 | $100.00 |
Technical Indicators
Market Signals| Indicator | RIGL | TRNS |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 38.81 |
| Support Level | $40.05 | $67.74 |
| Resistance Level | $49.50 | $94.58 |
| Average True Range (ATR) | 1.45 | 2.94 |
| MACD | -0.61 | -0.51 |
| Stochastic Oscillator | 17.89 | 19.15 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About TRNS Transcat Inc.
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.